7th Annual Pricing, Reimbursement & Market Access in Pharma 2012
March 5 - 6, 2012(Ended)
Madrid, Spain

The Annual Pricing, Reimbursement & Market Access in Pharma is a conference that covers topics such as:
- The concept of risk-sharing to accelerate the market access
- Developing an effective strategy to succeed in country-specific negotiations for price approval and granting of reimbursement
- Dealing with the increasing complexity and uncertainty in current pricing & reimbursement environment
- Critical insights into HTAs & their role in assessments of new drugs
- Make market access an integral part of the company & incorporate market access into the entire drug’s life cycle
- Cost-effectiveness measures & the impact on the industry
- The role of HTAs
- How can interaction between regulators and payers facilitate access to orphan drugs?
The Annual Pricing, Reimbursement & Market Access in Pharma brings together Vice Presidents, Senior Vice Presidents, Global Heads, Senior Executives, Directors, Heads, Managers and Senior Managers of: Reimbursement, Pricing, Commercial Pricing Pricing Strategists, Market Access, Outcomes Research, Health Economics, Governmental Affairs, Regulatory Affairs, Public Policy Directors, Public Affairs, Governmental bodies, Operations and Regulatory bodies.
Venue
Not final
Address
Madrid,
Spain
Spain
Organization
Categories
Concurrent events
Important
Please, check the conference website for possible changes, before you make any traveling
arrangements
* Prices are for evaluation only.
Articles/News/Press releases
- Cochlear Implantation in Auditory Neuropathy
- Effect Of Traditional Egyptian Herbal Medicine on Treatment of Hepatitis C virus (HCV)
- Validation of Palliative Prognostic Index for Terminal Cancer Patients in Hospice Consultation Setting in Taiwan
- Absract : Percutaneous Nephrolithotomy(PCNL): 10 years Experience with 7200 cases, Report of Results and Complications in Southern Iran
- Corneal endothelial recovery in patients undergoing small incision cataract surgery comparison between diabetics and non diabetics.
- Effect of pegylated interferon and ribavirin used for treatment of chronic hepatitis C patients on semen parameters





